MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

News of the day

Tobira Therapeutics Inc. Announce Presentation of TBR-652 Data at European AIDS Conference

Princeton, NJ and San Diego, CA, November 12, 2009--Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers. The two studies, a single-ascending dose (SAD) study and the multiple-ascending dose (MAD) study, were undertaken to... more

Theratechnologies presents combined Phase 3 clinical results at European AIDS Conference

Montr more

Geron Collaborators Publish Data on hESC-Derived Glial Progenitor Cell Therapy in Cervical Spinal Cord Injury

MENLO PARK, Calif., November 11, 2009 - Geron Corporation (Nasdaq: GERN) today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord injury, reduced tissue damage within the lesion and improved recovery of locomotor function. These data provide preclinical proof-of-concept for the use of GRNOPC1, Geron's hESC-derived oligodendrocyte progenitor product,... more

Industry news search

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Recent news

To keep up to date with news from this category use our RSS Feed to keep up to date

Simcyp Simulator aids in preclinical ADME assessment of Genentech compound
November 11, 2009--A recent paper, by researchers at Genentech, describes the preclinical evaluation of the pharmacokinetic properties of GDC-0449, a potent selective Hedgehog signalling pathway inhibitor which is being...

AlphaVax Progresses a Prophylactic HSV Vaccine
November 04, 2009--The development of an effective prophylactic vaccine against herpes simplex virus (HSV) is a key product opportunity for which the AlphaVax vector platform is ideally suited. [HSV Program]. Recently,...

ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
Tuesday 3 November 2009 -- Today, ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, was officially launched. Dr Dominique Limet, the Chief Executive Officer of ViiV...

ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST
RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho) positive fetal red blood...

PRIMA BIOMED SECURES JAPANESE PATENT FOR CANCER VAC
October 22, 2009--Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that its subsidiary company, Cancer Vac Pty Ltd, has received a Decision to Grant from the Japanese Patent Office...

Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its HIV vaccine were...

Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.

Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
Durham, NC and Paris, France- October 21, 2009 -- Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing...

Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...

Sernova's Cell Pouch System(tm) and Sertolin(tm) Preclinical Efficacy Presented at Leading International Islet Transplant Conference
LONDON, ONTARIO--(Oct. 20, 2009) - Sernova Corp. (TSX VENTURE:SVA - News) is pleased to provide a summary of results of islet transplantation studies related to its Cell Pouch System(TM) and Sertolin(TM) technologies...

BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...

Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...

Tarix Pharmaceuticals receives IND to treat HIV patients with persistently low CD4 counts
Brookline, MA, March 21, 2008 -- Tarix Phamaceuticals announced that it has received an approval of an IND to begin a Phase Ia dose escalation study to evaluate the safety of TXA127 in HIV patients maintained on HAART...

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us